首页> 外文期刊>Chemical engineering journal >Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy
【24h】

Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy

机译:热敏磁性脂质体用于双靶向脑肿瘤化疗中的交替磁场诱导药物递送

获取原文
获取原文并翻译 | 示例
           

摘要

The nonspecific distribution and non-targeted heating of chemotherapeutic agents in the human body commonly produce adverse side effects during brain cancer management. Even though an external magnetic field can partially gather extracellular magnetic drug carriers near brain tumor, magnetic guidance alone still cannot precisely identify and target either tumors or healthy tissues due to a lack of selectivity. In this study, we successfully developed thermal and magnetic dual-responsive thermosensitive magnetic liposomes (TML), which co-encapsulates Camptosar (CPT-11) and citric acid-coated magnetic Fe3O4 nanoparticles within the aqueous core and surface-conjugated with Cetuximab (CET) for recognizing over-expressed epidermal growth factor receptors on cancer cell surface. This drug carrier system can control the release of encapsulated drug when exposed to a high-frequency alternating magnetic field (AMF) that elevates the temperature of the liposomal membrane and triggers drug release from TML after their selective endocytosis by cancer cells. By detailed characterizing the physico-chemical and biological properties of liposomes, we demonstrated the liposomal formulation is with high biocompatibility and showed no hemolysis in vitro. Enhanced intracellular uptake of TML-CPT-11-CET by human primary glioblastoma cells (U87) also supported targeted delivery through CETmediated endocytosis. The treatment of TML-CPT-11-CET solutions by AMF in vitro showed rise in solution temperature and enhanced drug release, which enhanced cytotoxicity of CPT-11 toward U87 though cell apoptosis as revealed from flow cytometry analysis of apoptotic cells and Western blot studies of marker proteins. Finally, the in vivo therapeutic efficacy was demonstrated in mice orthotopic xenograft brain tumor model from IVIS and PET/MRI studies.
机译:在人体中的非特异性分布和非靶向加热的化学治疗剂通常在脑癌管理中产生不良副作用。尽管外部磁场可以部分地聚集脑肿瘤附近的细胞外磁性药物载体,但由于缺乏选择性,单独的磁引导仍然不能精确识别和靶向肿瘤或健康组织。在该研究中,我们成功地开发了热和磁性双响应热敏磁性脂质体(TML),其共同包封捕捉捕获捕捉捕获捕获的柠檬酸(CPT-11)和柠檬酸涂覆的磁性Fe3O4纳米颗粒,并用甲磺蛋白(CET)表面缀合(CET )为了识别癌细胞表面上的过表达表皮生长因子受体。该药物载体系统可以在暴露于高频交流磁场(AMF)时控制封装药物的释放,以升高脂质体膜的温度并在其通过癌细胞选择性内吞作用之后从TML中捕获药物释放。通过详细表征脂质体的物理化学和生物学性质,我们证明了脂质体制物具有高生物相容性,并且在体外没有溶血。通过CET介导的内吞作用,增强了人母发胶质母细胞瘤细胞(U87)的TML-CPT-11-CET的细胞内摄取。在体外用amf治疗TML-CPT-11-CET溶液的溶液温度和增强的药物释放的升高,该药物释放增强了CPT-11的细胞毒性,尽管细胞凋亡,从细胞凋亡细胞和Western印迹研究的流式细胞仪分析揭示标记蛋白。最后,在来自Ivis和PET / MRI研究的小鼠原位异种移植脑肿瘤模型中证明了体内治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号